Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Akouos stock | $19.91

Own Akouos stock in just a few minutes.

Fact checked

Akouos, Inc is a biotechnology business based in the US. Akouos shares (AKUS) are listed on the NASDAQ and all prices are listed in US Dollars. Akouos employs 54 staff and has a market cap (total outstanding shares value) of USD$699.7 million.

How to buy shares in Akouos

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Akouos. Find the stock by name or ticker symbol: AKUS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Akouos reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$19.91, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Akouos, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Akouos. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Akouos share price

Use our graph to track the performance of AKUS stocks over time.

Akouos shares at a glance

Information last updated 2020-12-03.
Latest market closeUSD$19.91
52-week rangeUSD$16.59 - USD$30.67
50-day moving average USD$19.344
200-day moving average USD$21.0765
Wall St. target priceUSD$33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.932

Buy Akouos shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Akouos stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Akouos price performance over time

Historical closes compared with the close of $19.91 from 2020-12-09

1 week (2021-01-12) 9.10%
1 month (2020-12-18) 7.51%
3 months (2020-10-19) 1.69%
6 months (2020-07-17) -5.73%
1 year (2020-01-16) N/A
2 years (2019-01-16) N/A
3 years (2018-01-16) N/A
5 years (2016-01-16) N/A

Akouos financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$699.7 million

TTM: trailing 12 months

Shorting Akouos shares

There are currently 1.6 million Akouos shares held short by investors – that's known as Akouos's "short interest". This figure is 2.2% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Akouos shares can be evaluated.

Akouos's "short interest ratio" (SIR)

Akouos's "short interest ratio" (SIR) is the quantity of Akouos shares currently shorted divided by the average quantity of Akouos shares traded daily (recently around 90190.213010938). Akouos's SIR currently stands at 17.37. In other words for every 100,000 Akouos shares traded daily on the market, roughly 17370 shares are currently held short.

However Akouos's short interest can also be evaluated against the total number of Akouos shares, or, against the total number of tradable Akouos shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akouos's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Akouos shares in existence, roughly 50 shares are currently held short) or 0.0604% of the tradable shares (for every 100,000 tradable Akouos shares, roughly 60 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Akouos.

Find out more about how you can short Akouos stock.

Akouos share dividends

We're not expecting Akouos to pay a dividend over the next 12 months.

Akouos overview

Akouos, Inc., a precision genetic medicine company, develops gene therapies to restore, improve, and preserve physiologic hearing for people worldwide. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site